Tag: Eli Lilly and Co

Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio

Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections